The association of A6986G single nucleotide polymorphism of CYP3A5 gene with tacrolimus blood level in kidney transplant patients in west Azarbaijan

Abstract

Renal transplantation is selected for treatment of several patients’ with end-stage renal disease (ESRD) and immunosuppressive drugs such as tacrolimus is subscribed for prevention of allograft rejection. Metabolism of this drug is commonly performed by products of the CYP3A4/5 genes. Because of genetic variations and importance of proper drug level regulation, aim of this study was determined investigation of relationship between A6986G CYP3A5 polymorphism and blood level of tacrolimus in transplanted patients.

Material & methods Blood samples of 70 patients were collected after renal transplantation. DNA samples were amplified after extraction via specified primers with PCR manner and finally, samples were sequenced. After that, data analysis were performed via SPSS software version 22.0. Results Obtained consequences showed that presence of A6986G CYP3A5 polymorphism was not effective in allograft rejection (P= 0.091) and viral infection (P= 0.228) of transplanted patients. In addition, this polymorphism has not statistically significant correlation with blood concentration of tacrolimus in second (P= 0.228), fourth (P= 0.736), and eighth (P= 0.978) week after starting treatment in transplanted patients.